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Executive Summary  
 
The shift in healthcare towards cost-savings mechanisms is hindering business 
operations of pharmacies in Kentucky, especially independent pharmacies. 
Independent pharmacists have reported that the operations of pharmacy benefit 
managers within Kentucky Medicaid networks have created financial hardships for 
their pharmacies and there is a threat of closure that could be associated with a 
potential access barrier to pharmacy services for Medicaid beneficiaries. During 
legislative meetings, much focus was on this issue and several bills are currently 
being drafted to correct this issue. It is important to define independent pharmacy 
and describe, geographically and in terms of utilization, chain and independent 
pharmacies in the Kentucky Medicaid network. Describing independent and chain 
pharmacies in the Kentucky Medicaid network provides insight for upcoming 
legislative issues and provides additional value to public health efforts.  
 
Medicaid pharmacy claims data for the 2017 fiscal year (July 2016- June 2017) were 
examined subsequent to defining “independent pharmacy” to determine if the 
closing of independent pharmacies would impact the delivery of medications to the 
Kentucky Medicaid population. ArcGIS software was utilized to map the radius 
between pharmacy types throughout Kentucky. Regional claims data was used to 
define the percent of chain and independent pharmacies within regions.  Claim 
counts and total expenditures were evaluated to identify potential differences in the 
types of medications supplied to the Medicaid population by chains and 
independent pharmacies and/or potential differences in the utilization of pharmacy 
types.  
 
According to distance requirements set by the Department for Medicaid Services 
contracts with Managed Care Organizations, there would not be an access issue if 
independent pharmacies were to close. However, when the proportions and 
utilization of independents and chains are described regionally, results suggest a 
chain pharmacy access to be a barrier for rural regions of the state. Descriptions of 
the most common medications within regions by total spend and claim count 
implies essential services are also provided by independent pharmacies compared 
to chains.  
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Introduction  
 
Pharmacy benefit managers (PBMs) grew in the early 2000s, when the rate of 
healthcare costs exponentially increased. With the increase in healthcare costs, the 
cost of prescription drugs began to significantly grow at a rate higher than wages1. 
By 2014, large employers reported spending 20 percent of their total health care 
spending on pharmacy costs 2.  Strategies to solve this problem included either 
shifting costs to patients or restructuring the prescription drug supply chain to 
implement cost-saving mechanisms. The Affordable Care Act set various payroll 
costs, deductibles, and out of pocket maximums, yielding the latter solution.  
 
PBMs were marketed as a cost savings mechanism and placed themselves within the 
pharmaceutical supply chain without much resistance due to the need for cost 
savings. PBMs provide the following services for contracted companies:  interfacing 
with plan sponsors, contracting with other parties in the prescription drug supply 
chain, maintaining eligibility, monitoring the plan sponsor’s plan design, reviewing 
and paying claims, reviewing and deciding which medications are most effective for 
each therapeutic use, negotiating rebates with manufacturers, adjudicating 
pharmacy claims, and improving quality. PBMs often operate a mail-order pharmacy 
and hold numerous contracts with retail pharmacy chains. Insurance companies, 
retail pharmacies, private entities, or manufacturers may own PBMs. Due to their 
place in the pharmaceutical supply chain, PBMs have become the most 
knowledgeable party involved in prescription drug supply chain3.  
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Figure 1: Pharmaceutical Supply Chain and Reimbursement Model 
 
Figure 1: Illustrates the complexity of the supply chain. Blue arrows represent movement a 
prescription drug product. Green arrows illustrate the flow of payment or rebates between entities. 
Red arrows represent a contract between two entities. 
 
To describe the operations of PBMs, an understanding of the prescription drug 
supply chain is essential. The pharmaceutical supply chain and reimbursement 
model is displayed in Figure 1. Prescription drug products are developed by a 
manufacturer. Wholesalers purchase these products from manufacturers. 
Purchasing from the wholesaler can occur directly from a pharmacy or pharmacies 
can contract through group purchasing organizations, which increases purchasing 
and bargaining power. The latter mechanism is often how independent pharmacies 
choose to purchase products, in an attempt to increase bargaining and purchasing 
power. Beneficiaries of a health plan purchase the product from a pharmacy. 
Pharmacies charge a health plan a dispensing fee for prescriptions and this fee is 
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often negotiated through a PBM. Independent pharmacies often contract with PBMs 
through pharmacy services administrative organizations (PSAOs) to also increase 
bargaining power by functioning as an aggregate entity of multiple independent 
pharmacies.  
 
PBMs hold a variety of contracts with other parties involved in the prescription drug 
supply chain. A typical PBM contracts with the insurance companies, suppliers, 
pharmacies, and PSAOs. Managed care organizations (MCOs) contract with PBMs 
and select a processing plan option.  Each contract may be very different. MCOs 
negotiate for reimbursement processing, the level of drug ingredient cost, as well as 
dispensing fees may be set under various formats, therefore the same drug for the 
same person dispensed from the same pharmacy but processed for different 
managed care organizations can have different reimbursements. The price of 
prescription drugs paid by the consumer is determined by a constellation of 
negotiated contracts between manufacturers, PBMs, wholesale distributors, 
pharmacies, and health plan sponsors. The price charged by each entity in the chain 
is largely driven by the ability of contracting entities to sell specific volumes of 
certain drugs or achieve a certain share of a specific market. It is also affected by the 
value each entity brings to the subsequent actors in the supply chain. 
 
In Kentucky, the Department of Medicaid Services (DMS) contracted with MCOs for 
pharmacy benefit delivery for the fiscal year 2016-2017 to manage pharmacy 
benefits for Medicaid beneficiaries. The Kentucky Medicaid Fee for Service, which 
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previously managed the entire Medicaid population’s medical and pharmacy 
benefits, only retained approximately 100,000 members and the remaining of the 
population, approximately 1.6 million members, were managed through various 
MCOs.  This contract between DMS and MCOs was on a capitation basis and set 
minimum medication and service coverage, thus limiting the potential fiscal impact 
on DMS. DMS did not mandate a specific PBM or specific reimbursement 
mechanisms. A majority of these MCOs contracted with PBMs to facilitate 
management of pharmacy benefits. At the time of this investigation, there were 
three PBMs in Kentucky- Caremark, Express Scripts, and Magellan.  Aetna Coventry, 
Humana CareSource, Passport, and WellCare contracted with CVS Caremark. 
Anthem contracted with Express Scripts. Kentucky Medicaid Fee for Service 
population contracted with Magellan to manage their prescription benefits.  
 
Pharmacy benefit managers report they have saved the state a large amount of 
money due to their ability to decrease costs since this change in structure.  However, 
independent pharmacists have lobbied heavily against PBMs, because they report 
an inability to negotiate contracts and reimbursement of medications due to their 
size and lack of bargaining power. These pharmacies report several instances where 
the pharmacy pays to dispense a prescription, which is tracked back to PBMs. These 
types of complaints against pharmacy benefit managers led to Senate Bill 117, which 
requires PBMs to be licensed in Kentucky through the Department of Insurance 
(DOI). This bill also allowed the DOI to regulate PBMs and implemented a process 
for pharmacies to appeal a maximum allowable cost (MAC). Despite this effort by 
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legislature, independent pharmacists continue to report being on the brink of 
closures and an inability to continue to function under this operations scheme. 
These pharmacists claim that closures could limit access to prescriptions and 
pharmacy services for Medicaid beneficiaries. 
 
The Centers for Medicare and Medicaid Services (CMS) require network adequacy at 
the member level. In the Social Security Act section 1902 (30)(A), payment for 
services under the plan must assure that payments are sufficient to enlist enough 
providers so that care and services are available under the plan at least to the extent 
that such services are available to the general population in the geographic area. To 
ensure network adequacy, the Department of Medicaid specifies that a pharmacy 
must be within a 60-mile radius of each beneficiary’s home address. This 
requirement in the MCO contracts meets the requirements set in KRS 304.17A-515 
that states that pharmacy services must be within 30 minutes or 30 miles of each 
enrollee’s place of residence or work.  
 
According to the Kentucky Board of Pharmacy, there is a pharmacy in every county 
with the exception of Robertson County. Aside from this fact, there has not been a 
distinction between independent and chain pharmacies within Kentucky.  
Pharmacies provide valuable contribution to the state’s public health efforts 
through dispensing medications, medication management, chronic medication 
management, and wellness counseling. Pharmacists are “medication experts” and 
provide necessary services to ensure proper management of chronic diseases and 
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ensure proper medication use. Independent pharmacists pride themselves for 
offering population-specific services that are needed within the area they serve, 
specifically in rural areas.4. The National Community Pharmacists Associations 
(NCPA) estimates approximately 22,000 independent pharmacies exist in the 
nation.5  This accounts for an estimated 36 percent of pharmacies in the nation.6 
This number has decrease from the year 2000 when the estimate was 24, 861 
independent pharmacies.  Additionally, the NCPA estimates that 1,800 independent 
pharmacies in the nation serve as the only pharmacy within a reasonable distance 
for their community4.  
 
Independent pharmacies may provide more extensive health care services, 
specifically in medically underserved areas.  The NCPA estimates that 87 percent of 
independents provide medication management services, 76 percent provide 
immunizations, 72 percent provide home delivery, 62 percent provide blood 
pressure monitoring, and 44 percent provide hospice services6.  
 
The value of independent pharmacies to public health creates concern subsequent 
to the recent closings of independent pharmacies. The threat of PBMs to 
independent pharmacies, and the potential for future threats, yields the question of 
how this would affect health care services and prescription medication availability 
for Kentucky’s Medicaid population. The aim of this project was to define 
independent and chain pharmacies and to conduct investigation on the location of, 
availability of, and utilization of independent and chain pharmacies. This project 
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evaluated the accessibility of personal and population-based health services 
provided by pharmacies to the Kentucky Medicaid population. Subsequent data and 
conclusions provide insight into public health efforts in providing potential policy 
development guidance and can inform, educate, and empower the public about 
pharmacy issues that affect the health of the Kentucky Medicaid population. 
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Methods  
 
Primary research objectives of this project were to determine the impact of 
independent pharmacies on access to medications to the Kentucky Medicaid 
population and to determine if there a difference in the types of medications 
supplied to the Medicaid population by chains and independent pharmacies. An 
empirical approach was utilized to address the study objective.  
 
In order to meet research objectives the following goals and methods were utilized. 
To conduct primary research by categorizing all Medicaid enrolled pharmacies as 
independent, chain, or miscellaneous pharmacies were manually categorized. The 
resulting categories were reviewed by the Director of Pharmacy at DMS. The 
distance required by MCO contracts was mapped with ArcGIS software, and chain 
and independent pharmacies were mapped independently and collectively. The 
percentage of independents and chain pharmacies were described within the 
Kentucky Medicaid regions by using descriptive statistics to define regional 
percents of chain and independent pharmacies. Utilization of pharmacies was 
examined by comparing drug expenditures and claim frequencies between chain 
and independent within regions. 
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Results  
 
A total of 1512 pharmacies participated in the Kentucky Medicaid Network through 
the 2017 fiscal year, 1207 of these were located within Kentucky, and 1041 of these 
pharmacies were categorized as “chain” or “independent”.  These pharmacies were 
categorized by pharmacy type according to the criteria listed in Table 1. This criteria 
was created and categorized by the researcher and criteria was validated by the 
Department of Medicaid. Based on these categories “independent pharmacy” 
represents pharmacies that are standalone locally owned and operated businesses. 
 
Table 1: Categories of Pharmacy Type 
 
Table 1: Lists all individual pharmacies that appeared in any claim during the 2017 fiscal year, 
grouped as “Chain", “Miscellaneous”, or “Independent”. 
 
Subsequent to categorizing pharmacies, the types were described on a state and 
regional level. It was found that 483 independents and 558 chains participated in 
the Medicaid network. A total of 166 pharmacies were categorized as miscellaneous 
and were not used for further investigation. Using the pharmacies’ addresses, 
registered with the Kentucky Board of Pharmacy and contracted with Kentucky 
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Medicaid, each type was separately mapped using ArcGIS software programming. 
After mapping each pharmacy at the appropriate geographical location within the 
state, a thirty-mile radius was mapped around each pharmacy. This mapping is 
visualized in figures 2 and 3. 
 
Figure 2: Chain pharmacies and a 30-mile radius around pharmacies 
 
Figure 2: Chain pharmacies are represented by blue dots and the blue circle defines a 30 
mile radius from each pharmacy. 
 
Figure 3: Independent pharmacies and a 30-mile radius around pharmacies 
 
Figure 3: Independents are red dots and the red circle around defines a 30 mile radius from 
each pharmacy. 
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Descriptions of pharmacy types at the regional level were described using the 
Medicaid managed care regions. Figure 4 visualizes the counties and geographical 
location of these regions. The word “rural” used through this project refers to the 
Purchase, Pennyrile, Bowling Green, Ashland, and Pikeville regions. The Louisville, 
Bluegrass, and Northern Kentucky regions are referred to as urban.  
 
Figure 4: Medicaid Managed Care Regions in Kentucky 
 
Figure 4:  Regions by which Medicaid defines the managed care regions. 
 
The total number of pharmacies within each region was equal to the sum of all 
independents and all chains within each region. The percent of independent and 
chain pharmacies were described within each region. Figure 5 represents the 
number of pharmacy type in each region. Fifty percent of the pharmacies in the 
Purchase region were independents, 52 percent in Pennyrile, 25 percent in 
Louisville, 56 percent in Bowling Green, 40 percent in Bluegrass, 34 percent in 
Northern Kentucky, 59 percent in Ashland, and 66 percent in Pikeville.  Within each 
of these regions utilization of pharmacy type was also determined by quantifying 
total spend and total claims for each type within each region. Regional spend and 
claim distribution is visualized in Table 3. 
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Figure 5: Number of Pharmacy Type Within Each Region 
 
Figure 5: Displays the number of independent and chain pharmacies within each region. 
 
Table 3: Total Spend and Claim Count by Region and Pharmacy Type 
 
Table 3: For each region the total spend and total claim count is defined for each Medicaid Manage 
Care Region. 
 
 
Regionally, top drugs by total spend and claim count were similar between chain 
and independent pharmacies. Rankings of the most common medications within 
regions by total spend and claim count are attached in Appendix 1. Appendix 2 
shows the frequencies of the top one and two drugs by claim count and total spend 
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for the state of Kentucky and for each pharmacy type and each location (rural and 
urban). Lidocaine was the number one drug for independents by total spend in the 
Purchase region. Paliperidone (Invega®) appeared on the top drugs by spend for 
independents. Vivitrol was the number one medication by total spend at 
independents for the Bowling Green Region.  
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Conclusions and Discussion  
 
PBMs threaten the business operations of independent pharmacies in Kentucky, the 
term “independent pharmacy” was defined in this project and descriptive statistics 
conducted to better understand the reliance the Kentucky Medicaid population had 
on independent pharmacies during the 2016-17 fiscal year for prescription services. 
Here, “independent” pharmacy was defined by creating categories of pharmacies 
based on criteria in Table 1.  Based on mapping as described above, network 
adequacy requirements were met in terms of contracts between the Department for 
Medicaid Services and the Managed Care Organizations. With the requirement for a 
pharmacy to be within a 30-mile radius, the entirety of the state was covered by 
only independent or only chain pharmacies. However, when broken down 
regionally concerns for access barriers were raised.  
 
There was a higher percentage of chain pharmacies in Kentucky, but the Purchase, 
Pennyrile, Bowling Green, Pikeville, and Ashland regions had a higher percentage of 
independent pharmacies. The Louisville, Bluegrass, and Northern regions, the more 
urban areas of Kentucky, were the only regions with higher percentages of chain 
stores. Rural regions compared to urban regions differed in which pharmacy type 
was utilized by Medicaid beneficiaries. Total spend and claim count was higher for 
chain pharmacies for the state. However, total spend was higher for independent 
pharmacies in the following regions: Bowling Green, Ashland, Pikeville. Claim count 
was higher at independent pharmacies in the following regions: Purchase, Pikeville. 
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These outcomes suggest that availability and utilization of independents is higher in 
rural areas and suggests that rural regions of Kentucky may depend more heavily on 
independent pharmacies. Therefore, despite contractual distances being met, rural 
Kentucky could experience access barriers to pharmacy services in the event that 
independents are not available. 
 
The differences between the top drugs by total spend and claim count in the 
Medicaid managed care regions may suggest the following differences between 
chains and independents. Lidocaine is frequently used for oral and topical non- 
sterile compounds. Lidocaine was the number one drug for independents by total 
spend, suggesting a higher rate of non-sterile compounding from independents in 
the Purchase region.  Invega Sustenna is an injectable long-acting anti-psychotic. 
Many independent pharmacies offer dispensing and administration of this 
medication and the reflected utilization of independent pharmacies for this 
medication reflect dependence on them for obtainment and administration. Vivtrol 
is another injectable medication that is commonly marketed by independent 
pharmacies. This medication is used as medication assisted treatment for alcohol 
and opioid dependence. Based on this project, it appears to be obtained more 
frequently from independent pharmacies.  
 
This project provides evidence that Kentucky’s Medicaid population depends on 
independent pharmacies for prescription medications, especially in rural regions of 
Kentucky. It is also possible that independent pharmacies in urban and rural regions 
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are relied upon for more extensive health care services. This is important to keep at 
the forefront as threats, such as PBMs, and any future potential threats arise that 
hinder business operations of independent pharmacies in Kentucky.  This project 
allowed for independent and chain pharmacies within Kentucky’s Medicaid 
Network to be distinguished and characterized at a regional level. Utilization was 
described using total spend and claim count at each pharmacy.  Characterizing 
access and utilization provides valuable contribution to the state’s public health 
efforts due to the necessary services that pharmacies provide, especially to our 
state’s Medicaid population. Pharmacies link health personnel to health services to 
provide healthcare that may be otherwise be unavailable and this project evaluated 
the accessibility of these population-based health services. Pharmacies provide 
valuable contribution to the state’s public health efforts through dispensing 
medications, medication management, chronic medication management, and 
wellness counseling. These services allow pharmacies to have a role in solving 
community health problems. It was important to characterize access and utilization 
within the state of Kentucky so that any changes within the market that may yield 
barriers to access can be anticipated and policies and plans can be developed. 
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Next Steps 
 
Additional research should be conducted on this subject matter, especially as 
legislation changes. Additional investigation is necessary to decide the role of DMS 
in this market driven issue and investigation into implementation of strategies that 
would have positive impact for rural independent pharmacies.  Services and 
programs provided by independents compared to chains should be analyzed. As, it 
is possible that independent pharmacies in rural regions of Kentucky support more 
primary care services through collaborative care agreements. Independents more 
commonly provide additional services such as delivery, medication therapy 
management, hormone therapy monitoring, and a variety of more extensive services 
compared to chain pharmacies. These services should specifically be characterized 
in medically underserved areas of Kentucky. As legislation attempts to make 
reimbursements through pharmacy benefit managers and managed care 
organizations more transparent, the level of reimbursement should be analyzed for 
chain and independent pharmacies, as well as at a regional level.   
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Limitations 
There are limitations of the data set for the use of the provided descriptive statistics. 
Claim count refers to the number of claims sent from a pharmacy to the Department 
of Medicaid and does not reflect the number of tablets or days covered for the 
medications dispensed. Data reflects only Medicaid claims and spend and could 
differ from commercially insured or cash-paying populations. 
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Appendix 1:  Top Drugs by Total Spend and by Claim Count in Managed Care  
Regions. 
 
Top Drugs by Total Spend and by Claim Count in Med Regions 
Region Type of 
Pharmacy 
Rank by 
Total 
Spend 
Drug Name Rank by 
Claim Count 
Drug Name 
 
P 
U 
R 
C 
H 
A 
S 
E 
Chain 1 Methylphenidate ER 1 Hydrocodone-
Acetaminophen 
2 Aripiprazole 2 Gabapentin 
3 Vyvanse 3 Lisinopril 
4 Lyrica 4 Amoxicillin 
5 Ventolin HFA 5 Omeprazole 
Independent 1 Lidocaine 1 Gabapentin 
2 Aripiprazole 2 Hydrocodone-
Acetaminophen 
3 Vyvanse 3 Omeprazole 
4 Methylphenidate ER 4 Lisinopril 
5 Symbicort 5 Ventolin HFA 
 
 
P 
E 
N 
N 
Y 
R 
I 
L 
E 
Chain 1 Methylphenidate ER 1 Gabapentin 
2 Aripiprazole 2 Amoxicillin 
3 Vyvanse 3 Hydrocodone- 
Acetaminophen 
4 Ventolin HFA 4 Lisinopril 
5 Lantus 5 Ventolin HFA 
Independent 1 Aripiprazole 1 Gabapentin 
2 Lantus 2 Hydrocodone-
Acetaminphen 
3 Methylphenidate ER 3 Omeprazole 
4 Ventolin HFA 4 Lisinopril 
5 Symbicort 5 Ventolin HFA 
 
L 
O 
U 
I 
S 
V 
I 
L 
L 
E 
Chain 1 Vyvanse 1 Hydrocodone-
Acetaminophen 
2 Symbicort 2 Cetirizine 
3 Aripiprazole 3 Gabapentin 
4 Methylphenidate ER 4 Amoxicillin 
5 Lantus Solostar 5 Ibuprofen 
Independent 1 Vyvanse 1 Gabapentin 
2 Symbicort 2 Cetirizine 
3 Aripiprazole 3 Hydrocodone-
Acetaminophen 
4 Methylphenidate ER 4 Omeprazole 
5 Invega Sustenna 5 Ventolin HFA 
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B 
O 
W 
L 
I 
N 
G 
 
G 
R 
E 
E 
N 
Chain 1 Symbicort 1 Gabapentin 
2 Ventolin 2 Amoxicillin 
3 Methylphenidate ER 3 Hydrocodone-
Acetaminophen 
4 Lantus 4 Lisinopril 
5 Lantus Solostar 5 Omeprazole 
Independent 1 Vivitrol 1 Gabapentin 
2 Symbicort 2 Hydrocodone- 
Acetaminphen 
3 Buprenorphine-
Naloxone 
3 Cetirizine 
4 Ventolin HFA 4 Omeprazole 
5 Lantus 5 Lisinopril 
 
 
B 
L 
U 
E 
G 
R 
A 
S 
S 
Chain 1 Suboxone 1 Gabapentin 
2 Methylphenidate ER 2 Lisinopril 
3 Buprenorphine-
Naloxone 
3 Omeprazole 
4 Symbicort 4 Amoxicillin 
5 Ventolin HFA 5 Hydrocodone-
Acetaminophen 
Independent 1 Suboxone 1 Gabapentin 
2 Buprenorphine-
Naloxone 
2 Omeprazole 
3 Symbicort 3 Ventolin HFA 
4 Gabapentin 4 Lisinopril 
5 Ventolin HFA 5 Cetirizine 
 
N 
O 
R 
T 
H 
E 
R 
N 
Chain 1 Methylphenidate ER 1 Gabapentin 
2 Lantus Solostar 2 Amoxicillin 
3 Symbicort 3 Ventolin HFA 
4 Ventolin HFA 4 Ibuprofen 
5 Aripiprazole 5 Lisinopril 
Independent 1 Symbicort 1 Gabapentin 
2 Ventolin 2 Ventolin HFA 
3 Dextroamphetamine-
Amphetamine ER 
3 Omeprazole 
4 Methylphenidate ER 4 Lisinopril 
5 Aripiprazole 5 Atorvastatin 
 
A 
S 
H 
L 
A 
N 
Chain 1 Symbicort 1 Gabapentin 
2 Ventolin HFA 2 Lisinopril 
3 Suboxone 3 Omeprazole 
4 Januvia 4 Cetirizine 
5 Lantus Solostar 5 Ibuprofen 
Independent 1 Suboxone 1 Gabapentin 
2 Symbicort 2 Omeprazole 
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D 3 Ventolin HFA 3 Lisinopril 
4 Zubsolv 4 Cetirizine 
5 Gabapentin 5 Ventolin HFA 
 
P 
I 
K 
E 
V 
I 
L 
L 
E 
Chain 1 Suboxone 1 Gabapentin 
2 Symbicort 2 Ibuprofen 
3 Januvia 3 Lisinopril 
4 Ventolin HFA 4 Hydrocodone-
Acetaminophen 
5 Lantus Solostar 5 Omeprazole 
Independent 1 Suboxone 1 Gabapentin 
2 Symbicort 2 Hydrocodone-
Acetaminophen 
3 Gabapentin 3 Ibuprofen 
4 Ventolin HFA 4 Lisinopril 
5 Buprenorphine-
Naloxone 
5 Omeprazole 
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Appendix 2:  Frequencies of Top 2 Drugs  By Claim Count and Total Spend 
 
 
Rank by Claim Count           
 All Chain Independent Rural Urban 
Drug Name 1st 2nd 1st 2nd 1st 2nd 1st  2nd 1st 2nd  
Amoxicillin   3   3       2   1 
Cetirizine    2   1   1       2 
Gabapentin 14 1 6 1 8   9 1 4   
Hydrocodone-APAP 2 4 2     4 1 4 1   
Ibuprofen   1   1       1     
Lisinopril   2   2       1   1 
Omeprazole   2       2   1   1 
Ventolin HFA   1       1       1 
           
Rank by Total Spend           
 All Chain Independent Rural Urban 
Drug Name 1st 2nd 1st 2nd 1st 2nd 1st  2nd 1st 2nd  
Methylphenidate ER 3   3       2   1   
Arirpiprazole  1 3   2 1 1 1 3     
Lidocaine 1       1   1       
Lantus   2   1   1   1   1 
Vyvanse 2   1   1       2   
Symbicort 3 6 2 2 1 4 2 4 1 2 
Ventolin HFA   3   2   1   2   1 
Vivitrol 1       1   1       
Suboxone 5   2   3   3   2   
Bup/Nal   1       1       1 
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